0000899243-23-005918.txt : 20230222 0000899243-23-005918.hdr.sgml : 20230222 20230222212102 ACCESSION NUMBER: 0000899243-23-005918 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230217 FILED AS OF DATE: 20230222 DATE AS OF CHANGE: 20230222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Glover Bradley CENTRAL INDEX KEY: 0001867698 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38914 FILM NUMBER: 23655685 MAIL ADDRESS: STREET 1: C/O CELULARITY INC. STREET 2: 170 PARK AVENUE CITY: FLORHAM PARK STATE: NJ ZIP: 07932 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celularity Inc CENTRAL INDEX KEY: 0001752828 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831702591 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 170 PARK AVE CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: (908) 768-2170 MAIL ADDRESS: STREET 1: 170 PARK AVE CITY: FLORHAM PARK STATE: NJ ZIP: 07932 FORMER COMPANY: FORMER CONFORMED NAME: GX Acquisition Corp. DATE OF NAME CHANGE: 20180912 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-17 0 0001752828 Celularity Inc CELU 0001867698 Glover Bradley C/O CELULARITY INC. 170 PARK AVENUE FLORHAM PARK NJ 07932 0 1 0 0 See Remarks Class A Common Stock 2023-02-17 4 A 0 300000 A 354076 D These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A Common Stock. The RSUs is subject to time-based vesting over a two-year period, with 50% vesting on the one-year anniversary of the grant date, and the remainder vesting on the two-year anniversary of the grant date, and subject to the Reporting Person's continuous service on each vesting date. These shares include 345,310 shares underlying RSUs granted under the 2021 Plan. Each RSU represents the right to receive one share of the Issuer's Class A common stock subject to vesting. Executive Vice President, Chief Operating Officer /s/ Kyle Fletcher, Attorney-in-Fact 2023-02-22